The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Checkpoint inhibitors in anal cancer
Immunotherapies currently lack a clear role in anal cancer treatment. In this interview, Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, discusses the use of checkpoint inhibitors in anal cancer, which when used in monotherapy cohorts, have shown mixed efficacy with varied patient responses. The recent POD1UM-303 trial (NCT04472429), focused on pre-treated patients, showing moderate but promising results. This suggests the potential for checkpoint inhibitors, combined with chemotherapy, to become a new standard, particularly for non-metastatic or unresectable cases, raising important questions about earlier-stage treatments.This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
